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Abstract Thirty-five percent of patients with Rett syn-
drome carry nonsense mutations in the MECP2 gene. We
have recently shown in transfected HeLa cells that read-
through of nonsense mutations in the MECP2 gene can be
achieved by treatment with gentamicin and geneticin. This
study was performed to test if readthrough can also be
achieved in cells endogenously expressing mutant MeCP2
and to evaluate potentially more effective readthrough
compounds. A mouse model was generated carrying the
R168X mutation in the MECP2 gene. Transfected HeLa
cells expressing mutated MeCP2 fusion proteins and mouse
ear fibroblasts isolated from the new mouse model were
treated with gentamicin and the novel aminoglycosides
NB30, NB54, and NB84. The localization of the read-
through product was tested by immunofluorescence. Read-
through of the R168X mutation inmouse ear fibroblasts using
gentamicin was detected but at lower level than in HeLa cells.
As expected, the readthrough product, full-length Mecp2
protein, was located in the nucleus. NB54 and NB84 induced
readthrough more effectively than gentamicin, while NB30
was less effective. Readthrough of nonsense mutations can be
achieved not only in transfected HeLa cells but also in
fibroblasts of the newly generated Mecp2
R168X mouse model.
NB54 and NB84 were more effective than gentamicin and
are therefore promising candidates for readthrough therapy in
Rett syndrome patients.
Keywords DNA binding.Drug development.Knockout.
Mutation.Molecular therapy.Pediatrics
Introduction
Rett syndrome (RTT) is a severe neurodevelopmental
disorder that almost exclusively affects females [1]. After
an initial period of normal or near-normal development
lasting 8–18 months, loss of hand function and language is
noted followed by a long period of stability in the clinical
status [2]. RTT is caused by mutations in the X-
chromosomal gene MECP2 encoding the methyl-CpG-
binding protein 2 (MeCP2) [3]. MeCP2 binds to methylated
CpGs in genomic DNA and is therefore part of the
epigenetic control of gene expression [4]. Deficient mouse
models that completely or partially lack Mecp2 recapture
features seen in humans including the delayed onset of
symptoms [5–8]. Remarkable results were obtained in a
mouse model in which the endogenous Mecp2 gene is
silenced by insertion of a lox-Stop cassette and then
conditionally activated [9]. The activation of MeCP2 expres-
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DOI 10.1007/s00109-010-0704-4sion leads to improvement of symptoms and has therefore
given hope that RTT is a treatable disorder. As 35% of RTT
patients carry nonsense mutations [10], a pharmacological
induced readthrough of premature stop codons is an attractive
treatment approach. In our previous study using transfected
HeLa cells, we have demonstrated that the aminoglycosides
gentamicin and geneticin suppress RTT-causing nonsense
mutations with efficiencies of up to 20% [11]. These findings
have since been reproduced by Popescu et al. [12]. They also
demonstrated that readthrough is possible in a lymphocyte
cell line derived from a Rett syndrome girl. However,
readthrough was not achieved when the dosage was reduced
to a level safe for human use. Gentamicin and other
aminoglycosides when employed as antibiotics in humans
have, especially when administered in higher dosages,
significant side effects, including nephrotoxicity and ototox-
icity, limiting their application for readthrough therapy.
In the present report, we therefore tested three novel
aminoglycosides—NB30, NB54, and NB84—that were
developed on the paromomycin scaffold by optimization
of structure–activity–toxicity relationship. Compared to the
parent compound paromomycin and to gentamicin, these
compounds display significantly lower toxicity and exhibit
higher readthrough activity [13, 14]. We also report on the
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Fig. 1 NB54- and NB84-mediated suppression of premature stop
mutations. Western blot analysis of protein samples prepared from
aminoglycoside-treated and untreated transiently transfected HeLa
cells, using a monoclonal anti-FLAG antibody or a specific antibody
detecting the C terminus of MeCP2. Thirty microgram of protein
extract was loaded. Arrows denote the full-length FLAG-MeCP2
protein as well as the truncated FLAG-MeCP2 isoforms. As a loading
control, GAPDH was detected in all samples. The cells were treated
for 24 h with 500 μg/ml of gentamicin (a), NB30 (a), NB54 (a–b), or
NB84 (b). The effect of 24-h drug treatment was quantified by
densitometric western blot analysis from at least three independent
experiments (c)
390 J Mol Med (2011) 89:389–398generation of a knock-in mouse model carrying one of the
most frequently occurring nonsense mutations in the Mecp2
gene, R168X, and readthrough studies in ear fibroblasts of
this mouse model.
Materials and methods
Gene targeting construct
A targeting vector was designed to generate a knock-in
mouse model carrying the most common nonsense
mutation associated with Rett syndrome (R168X). The
mutation introduces an in-frame UGA stop codon in
place of a codon for arginine (AGA). Genomic sequen-
ces were derived from a BAC plasmid containing the
whole genomic sequence of mouse Mecp2 (BAC-Klon
RPCI-23, RZPD). A PCR-amplified 921-bp XmaIg e -
nomic fragment (primer 1: MeCP2-LA1-F-(XmaI) 5′-
ATACCCGGGTGCCTTGGTTAAAATGGAGG-3′,p r i m -
er 2: MeCP2-LA1-R-(XmaI) 5′-GTCTCCCGG
GTCTTGCGCTTCTTGATG-3′) was subcloned in
pGEM-T easy (Promega) and used for site-directed
mutagenesis to replace adenine at position 502 within
exon 4 by thymine (c.502 A>T, MeCP2-A502Tmut: 5′-
AGCCCCTCCAGGTGAGAGCAGAAACCACC-3′). The
mutated fragment was fused to a 7.2-kb genomic fragment
generated by XmaI-NdeI digestion of the BAC plasmid.
This 8.1-kb fragment resulted in the 3′ region of
homology. The 5′ region of homology consisted of a
PCR amplified 1.1-kb NotI-AgeI Mecp2 fragment (primer
3: MeCP2-KA-F-(NotI) 5′-ATAGCGGCCGCGGGATGA
GATTAGCTGCT-3′, primer 4: MeCP2-KA-R-(AgeI) 5′-
ATAACCGGTTGGTGTCCAGCCTTTTTGGG-3′)spanning
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Fig. 2 Nuclear localization of readthrough full-length MeCP2-FLAG
fusion protein in drug-treated HeLa cells. Immunofluorescence of
HeLa cells transfected with MeCP2-WT-FLAG- (a–c) compared to
MeCP2-R168X-FLAG-expressing HeLa cells cultured under untreat-
ed (d–f) and drug-treated (g–i 500 μg/ml NB54; j–l 500 μg/ml NB84)
conditions. Treatment was performed for 24 h. Localization of FLAG
fusion proteins (left column) was visualized by using a monoclonal
anti-FLAG antibody and immunofluorescence microscopy. Because
the fusion protein was C-terminally FLAG-tagged, only full-length
MeCP2 proteins were detected. The nuclei were counterstained with
DAPI (middle column). Right column MeCP2-WT-FLAG expression
as well as treated MeCP2-294-FLAG overlaps with DAPI staining,
indicating a nuclear localization. Scale bars are 50 μm
J Mol Med (2011) 89:389–398 391from within intron 2 to intron 3. Surrounded by the homology
arms, the targeting vector contains a neomycin-resistance
cassette flanked by Flp-recombinase target (FRT) sites for
subsequent removal with Flp-recombinase. The vector was
linearized for electroporation at the 5′ end using ClaI.
ES cell culture and gene targeting
R1 mouse embryonic stem cells were electroporated with
50 μg of the linearized targeting vector, and colonies were
isolated after G418 selection as previously described [15].
Five G418-resistant clones were identified as homologous
recombinants by nested PCR amplification of a 1.9-kb
genomic fragment. The correct genomic location was
verified in the DNA of heat-lysed cells, by using forward
primers at positions outside the homology region (primer 5:
MeCP-Ki-KV1F 5′-CCAAGACAGGCTTTGACCC-3′,
primer 7: MeCP-Ki-KV2F 5′-CCCTAAAGTACATGAAG
GAACCC-3′) and reverse primers located in the neo
cassette (primer 6: neo2R 5′-GCAATCCATCTTGTT
CAATGGC-3′,p r i m e r8 :n e o 3 R5 ′-CCATCTTGTT
CAATGGCCGATC-3′). Both PCR reactions were per-
formed in 25-μl reactions and started with denaturing at
95°C for 30 s. Annealing was at 56°C for 45 s and
extension at 72°C for 2 min. For the first PCR step, we used 25
cycles, and 40 cycles were used for the second step.
Microinjection of selected ES cells into C57BL/6 blastocysts
and embryo transfer to pseudopregnant females was performed
by standard procedures [15]. Highly chimeric males were bred
to C57BL/6 female, and germ line transmission was
confirmed by PCR and sequencing. Heterozygous (Mecp2
+/−) F1 females were crossed with C57BL/6 males to obtain
hemizygous (Mecp2
R168X -/Y) male mutants. To remove the
neo cassette, heterozygous (Mecp2 +/−) females were mated
with FLIP-recombinase-expressing males. The genotype of
mutated mice was routinely determined by PCR analysis
using primer (primer 9: KI-Geno3F: 5′-GCCTGAAGGTTG
GACACGAAAGC-3′) and primer (primer 10: KI-Geno3R:
5′-GGGCTAGACT GAATATCTTTGGTTGGTAC-3′), yield-
ing two fragments. Presence of the wild-type allele was
revealed by amplifying a 265-bp fragment. A product of 313-
bp was found under mutated conditions. Mice used in the
experiments described here were backcrossed through a
minimum of 10 generations. Care and handling of the mice
were conducted in concordance with Institutional Animal
Care and Use Committee-approved protocols.
RNA analysis
Reverse transcriptase PCR (RT-PCR) was used to verify the
Mecp2 gene expression in mutant mice. Total RNA was
isolated from wild-type and mutant male brain using
peqGOLD TriFast™ reagent according to the manufac-
turer's protocol (peqlab, Erlangen, Germany). After cDNA
synthesis with oligo dT primers and AMV-reverse tran-
scriptase (Invitrogen, Darmstadt, Germany) a 1,455-bp
MECP2 cDNA fragment was amplified (MeCP2-CDS-F
5′-ATAGAATTCAATGGTAGCTGGGATGTTAGGG-3′
and MeCP2-CDS-R 5′-ATAGGATCCTCAGC
TAACTCTCTCGGTCACGG-3′) representing the whole
Mecp2 coding region.
Cell culture and fibroblast isolation
HeLa cells and mouse ear fibroblasts were maintained as
monolayer cultures growing in Dulbecco's modified Eagle's
medium (DMEM/low glucose, Cambrex Bio Science,
Verviers, Belgium) supplemented with 10% fetal bovine
serum (Biochrom, Berlin, Germany) and 1% L-glutamine
(PAA, Pasching, Austria). Cells were incubated at 37°C in
an atmosphere of 5% CO2. Primary mouse ear fibroblasts
were isolated from both male wild-type and knock-in mice.
Using scalpels, pieces of individual ears were cut into small
fragments to expose fibroblasts, which were separated on
25-cm
2 tissue culture flasks with the aid of a sterile pipette.
The fibroblasts were allowed to grow for 8–10 days. HeLa
cells and fibroblasts were subcultured using trypsin when
they were 85–90% confluent.
Transfection and drug treatment
For the majority of experiments, assaying readthrough HeLa
cells were seeded at 3×10
5 cells/well in six-well culture
plates and transfected with the appropriate eukaryotic
expression vectors as described previously [11]u s i n g
Fig. 3 Gene targeting and Flp-mediated recombination at the Mecp2
locus. The diagram shows the wild-type Mecp2 genomic locus, the
targeting vector, and the targeted locus before and after Flp-mediated
recombination. The 5′ and 3′ regions of homology are shown in light
gray. Small arrows indicate primers used to confirm gene targeting
and Flp-mediated recombination, and to screen the genotype (a).
Homologous recombination was verified by nested PCR of genomic
DNA of the selected ES cell clones; primers 5/6 and 7/8 were as
shown in a. The 1.9-kb band is from the mutated allele. The primer
sets were designed not to amplify the wild-type Mecp2 gene. E5, E7,
E32, and E38 are names of ES clones, while c and b indicate a
plasmid DNA control demonstrating the mutant PCR fragment and
blank. Primer set 9 and 10 were used for the genotyping PCR after
FLP recombination (c). The 313-bp band represents the mutant allele
(Hem hemizygous male, Het heterozygous female) containing the
remaining FRT site, while the 265-bp band represents the wild-type
allele (WTwild type). To confirm the presence of Mecp2 mRNA in the
brain of two wild-type (WT (+/Y)) and two R168X (−/Y) mutant male
mice, total RNA was extracted from brain of male wild-type and
mutant mice and used for cDNA synthesis and RT-PCR (d). Western
blot analysis (e) and immunofluorescent staining (f) demonstrated the
absence of wild-type MeCP2 protein in nuclear extracts of hemizy-
gous brains (Sup supernatant, Nuc nuclear extract) and in nuclei of
mouse ear fibroblast using an antibody recognizing the N terminus of
MeCP2. Note that no additional truncated protein was detected
b
392 J Mol Med (2011) 89:389–398Effectene reagent (QIAGEN, Hilden, Germany) following
manufacturer's protocols. Transfected HeLa cells were
cultured in fresh media and media containing 500 μg/ml
NB54 or NB84 (provided by Timor Baasov, Haifa, Israel) for
24 h. Mouse ear fibroblasts (1×10
6 cells/10-cm culture plate)
were treated with a daily dose of different concentrations (0–
800 μg/ml) of gentamicin (SIGMA, Taufkirchen, Germany),
NB54, and NB84 for 4 days. During treatment, fibroblasts
were refed with growth media containing the desired drug
dilution with replacement every 48 h.
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J Mol Med (2011) 89:389–398 393Preparation of cell lysates and nuclear proteins
After treatment, cell lysates of transfected HeLa were
obtained using RIPA buffer as described previously [11].
For detecting readthrough in drug-treated mouse ear
fibroblasts, nuclear proteins were prepared as described
previously [16]. Protein concentration was measured using
the BC assay (Uptima, Montlucon cedex, France), follow-
ing manufacturer's protocols.
Western blotting and antibodies
An amount of 30 μg of protein from each sample was
assayed via SDS–PAGE followed by western blot analysis.
Membranes (Schleicher and Schuell, Dassel, Germany)
were blocked with 5% nonfat milk/TBSTand probed with a
primary antibody overnight (anti-Flag M2 and anti-GAPDH,
SIGMA, Taufkirchen, Germany, 1:1000; anti-MeCP2
(D4F3), Cell Signaling Technology, Danvers, MA, USA.,
1:1000) followed by secondary antibody incubation for 1 h
(horseradish peroxidase-conjugated donkey anti-mouse IgG
and goat anti-rabbit IgG, Jackson Immuno-Research Labora-
tories, West Grove, PA, USA). All antibodies were used at
concentrations recommended by the manufacturer. Immuno-
reactive bands were visualized using enhanced chemilumi-
nescence (Lumi-Light Western Blotting Substrate, Roche
Diagnostics, Heidelberg, Germany). The efficiency of the
readthrough was estimated by comparing the expression of
total MeCP2 to the expression of full-length protein using
densitometry (Camera: Fuji LAS-1000plus; Programm: Aida
Version 3.10).
Immunofluorescent cell staining
Immunofluorescence experiments of drug-treated transfected
HeLa cells were carried out as previously described [11]. For
the staining of treated mouse ear fibroblasts, cells were
grown on 18-mm cover slips and fixed in 4% paraformal-
dehyde for 15 min at RT. After washing three times with
PBS, the cells were blocked (PBS, 5% normal goat serum,
0.3% Triton X-100) for 1 h at RT. Following an overnight
incubation at 4°C with a cocktail of primary antibodies (anti-
Tubulin, 1:2000, SIGMA, Taufkirchen, Germany; anti-
MeCP2 (D4F3), Cell Signaling Technology, Danvers, MA,
USA, 1:200; dilution in 1% BSA/PBS with 0.3% Triton X-
100), cells were washed three times with PBS and incubated
with the corresponding secondary antibody (goat anti-mouse
IgG Cy3, 1:500, Jackson Immuno-Research Laboratories,
West Grove, PA, USA; Alexa Fluor 488 goat anti-rabbit IgG,
Molecular Probes Inc., Eugene, OR, USA, 1:500; dilution in
1% BSA/PBS with 0.3% Triton X-100) at RT for 1 h. After
triple washing with PBS, the prepared cover slips were
mounted onto slides with ProLong® Gold antifade reagent
with DAPI (Molecular Probes Inc., Eugene, OR, USA). The
stained cells were analyzed using fluorescent microscopy
(Zeiss, Göttingen, Germany).
Results
NB54 and NB84 show increased readthrough
of RTT-causing premature stop mutations
To evaluate the readthrough efficiency of NB30, NB54, and
NB84, HeLa cells were transfected with eukaryotic expres-
sion vectors carrying N-terminally FLAG-tagged wild-type
MECP2 cDNA or mutated MECP2 cDNAs. The mutations
introduce an in-frame UGA stop codon in place of a codon
for arginine at position 168, 255, 270, and 294 of MeCP2.
HeLa cells were grown in the presence of 500 μg/ml
gentamicin, NB30, NB54, and NB84 for 24 h. Western blot
analysis confirmed the absence of full-length MeCP2 in
untreated cells expressing mutated FLAG-MeCP2 isoforms
(Fig. 1a, b). After treatment, full-length FLAG-MeCP2 was
detected using an anti-FLAG and an anti-MeCP2 C-
terminal antibody. The readthrough efficiency of NB30
was significantly lower compared to gentamicin, and this
compound was therefore not used for further experiments
(Fig. 1a). NB54 and NB84 were found to be more effective
than gentamicin. NB54-induced readthrough ranged from
16.8% to 27.6%; NB84 was most effective with read-
through between 24% and 32.1% (Fig. 1b). The highest
level of suppression was detected in the R294X mutation,
while NB84 and NB54 were less effective in the R168X
and R270X mutations. (Fig. 1c).
The subcellular localization of MeCP2 proteins that
resulted from readthrough in transfected HeLa cells was
investigated by immunofluorescent staining. For this purpose,
HeLa cells were transfected with eukaryotic vectors express-
ing C-terminally FLAG-tagged MeCP2 fusion proteins,
whereby only wild-type MeCP2-FLAG and readthrough
proteins were detected using a FLAG-specific antibody. In
untreated cells, MeCP2-FLAG fusion protein was only
detected in the nucleus of the cells transfected with wild-
type MeCP2 (Fig. 2a–c), and no signal was detected in cells
expressing a mutated MeCP2 isoform (Fig. 2d–f). After
treatment with NB54 and NB84, some cells showed again
nuclear-localized fusion protein (Fig. 2g–l).
Generation of Mecp2
R168X knock-in mice
To test the efficiency of the novel compounds in a more in
vivo-like system, we generated a mouse model for Rett
syndrome by introducing the truncating mutation R168X
into the murine Mecp2 protein (Mecp2
R168X, Fig. 3a). This
engineered truncation retains the methyl-CpG-binding
394 J Mol Med (2011) 89:389–398domain but eliminates the C-terminal part of the coding
sequence including the transcription repressor domain and
nuclear localization signals. The Mecp2 transcript in brain
was confirmed by RT-PCR using cDNA prepared from total
RNA, and the mutation was detected by sequencing
(Fig. 3d). Because it is a C-terminally truncating mouse
model, we used an antibody recognizing the amino-terminal
half of Mecp2 that should be preserved with the truncation.
Western blot analysis showed a 72-kDa full-length protein
in male wild-type mice, but failed to detect a wild-type or
truncated protein of expected 18-kDa in the mutant males
(Fig. 3e). Staining of ear fibroblasts with the same antibody
confirmed the absence of Mecp2 protein in mutant cells
(Fig. 3f). The phenotype of knock-in mice will be reported
elsewhere, and preliminary observations indicate that the
mouse model shows characteristics as described in other
Mecp2-deficient mice.
Readthrough treatment of fibroblasts isolated
from the Mecp2
R168X knock-in mice
Isolated mouse ear fibroblasts from male wild-type and
Mecp2
R168X knock-in mice were treated for 4 days with
different concentrations of gentamicin, NB54, and NB84.
Using an anti-MeCP2 antibody detecting a C-terminal epitope
of the protein, we found a dose-dependent re-expression of
Mecp2 in nuclear extracts (Fig. 4a). Compared to gentamicin
(0.6%) and NB54 (2.5%), the highest level of suppression
was observed after treatment with NB84 (5%; Fig. 4b).
Using NB84, full-length Mecp2 expression was already
detected at the lowest dose of 100 μg/ml. Immunofluorescent
staining using an antibody directed against the carboxy-
terminal epitope of Mecp2 and fluorescent microscopy
confirmed the re-expression of endogenous Mecp2 with
correct location in the nucleus (Fig. 5).
Discussion
Approximately one third of inherited diseases result from
premature termination codon mutations. Aminoglycosides
have emerged as vanguard pharmacogenetic agents in
treating human genetic disorders due to their unique ability
to suppress translation termination induced by nonsense
mutations. In preclinical and several pilot clinical studies
[17–21], this therapeutic approach shows promise in
phenotype correction by promoting otherwise defective
protein synthesis. However, the most critical factor that
largely limits the potential of aminoglycosides for suppres-
sion therapy is their high human toxicity [22, 23].
Nevertheless, the clinical drug gentamicin is frequently
used for proof-of-concept experiments in various disease
models and in clinical trials [18–21], while no systematic
study has been performed to tune aminoglycoside structures
for better readthrough activity and lower toxicity. Recently,
we hypothesized that by separating the structural elements
of aminoglycosides that induce readthrough from those that
affect toxicity, we might reach potent derivatives with
improved readthrough activity and reduced toxicity [13,
24]. By keeping this line of research, we systematically
developed the lead compounds NB30, NB54, and NB84
that exhibit significantly reduced toxicity and superior
readthrough efficiency than that of gentamicin [13, 24].
Previously, we [11] and others [12] have reported that
readthrough of different RTT-causing premature stop
codons can be achieved by different aminoglycosides
including gentamicin in transient transfection assays. In
this study, we provide the first comparative evaluation of
novel aminoglycosides NB30, NB54, NB84, and gentami-
cin in a number of clinically relevant RTT models.
It is noteworthy that the testing of readthrough therapy in
fibroblasts from RTT patients was not feasible because
MECP2 is an X-linked gene, meaning that due to random
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Fig. 4 Drug-mediated re-expression of endogenous MeCP2. Western
blot analysis of nuclear extracts prepared from aminoglycoside-treated
and untreated mouse ear fibroblasts generated from wild-type and
Mecp2
168 male mice: Immunoreactivity was detected by using a
monoclonal anti-FLAG antibody and a specific antibody detecting the
C terminus of MeCP2. Thirty microgram of protein extract was loaded
into each lane. Arrows denote the full-length endogenous MeCP2
protein. The cells were treated for 4 days with 0–800 μg/ml of
gentamicin, NB54, or NB84 (a). The effect of drug treatment was
quantified by densitometric developed western blot analysis from at
least three independent experiments (b)
J Mol Med (2011) 89:389–398 395X-chromosome inactivation in female patient fibroblast
cultures, ∼50% of wild-type MeCP2 expression is found.
Reliable detection of low-level readthrough is therefore
difficult if not impossible. Since no mouse model suitable
for readthrough therapy was available, we generated a
knock-in mouse carrying the nonsense mutation that is most
frequently found in RTT patients, R168X. The preliminary
characterization of the mice showed that the male mice
have a phenotype comparable with that reported from other
Mecp2-deficient mice including tremor, motor impairments,
hypoactivity, anxiety-related behavior, hind limb clasping,
and breathing irregularities [25]. In brain tissue of the
Mecp2
R168X knock-in mice, we were not able to detect a
shortened Mecp2 protein indicating that it is degraded
rapidly.
Initially, mouse ear fibroblasts isolated from the new
mouse model were treated with gentamicin. Using immuno-
fluorescent and western blot analysis, we were able to detect
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Fig. 5 Nuclear localization of endogenous Mecp2 in drug-treated
mouse fibroblasts. Immunofluorescent staining of mouse ear fibro-
blasts generated from wild-type and Mecp2
168 male mice. Cells were
treated 4 days with 800 μg/ml gentamicin (i–l), NB54 (m–p), and
NB84 (q–t), respectively. Localization of endogenous MeCP2 protein
(first column) was visualized by using a specific MeCP2 antibody
detecting the C-terminal part of the protein and immunofluorescent
microscopy. The nuclei and the cytoskeleton of the cells were
counterstained with DAPI (second column) and tubulin (third
column). All three stainings are merged (last column). No MeCP2-
specific staining was detected in untreated fibroblasts (e–h). Scale
bars are 50 μm
396 J Mol Med (2011) 89:389–398full-length Mecp2, showing that readthrough of the R168X
mutation is possible in fibroblasts. The Mecp2 protein was
found to be correctly targeted to the nucleus. However, the
efficiency of gentamicin-induced readthrough was low even
at concentrations as high as 800 μg/ml, a dose that is above
the range that is considered safe for clinical use (Fig. 4)[ 26].
To search for more efficient drugs, we used our established
transient transfection system to test the suppression efficien-
cies of three novel aminoglycosides that were designed
especially for readthrough therapy [13, 14]. NB30, NB54,
and NB84 are pseudo-trisaccharide derivatives of the clinical
aminoglycoside paromomycin. We found that NB30 induces
less readthrough than gentamicin, but NB54 and NB84 were
more effective. These results are in agreement with studies
using similar assays for other genetic disorders [13, 27]. As
in our previous study [11], we found that the efficiencies
depend on the stop codon and its surrounding sequence as
described in other genetic disorders [11, 28].
Fibroblasts isolated from male Mecp2
R168X knock-in
mice were then treated with NB54 and NB84, and the
efficiency was compared to that of gentamicin. Both NB54
and NB84 were found to suppress the Mecp2-R168X stop
mutation more efficiently than gentamicin. The level of
readthrough was dose-dependent and highest with NB84.
Thus, NB54 and NB84 are promising compounds for
readthrough therapy in RTT and are currently being tested
in vivo in male Mecp2
R168X knock-in mice.
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